BioPharm Systems Launches New Tool for Transferring Oracle Clinical Data
BioPharm Systems announced that it has launched a new solution which enables life sciences companies that use Oracle Clinical, Oracle's clinical data management system, to copy studies between Oracle Clinical environments.
The Oracle Clinical Study Copy Tool is a flexible application that can be used for tasks such as transferring clinical studies from one Oracle Clinical instance to another, archiving a global library or clinical studies, and refreshing patient data in a non-production environment.
"We originally developed this Oracle Clinical application for a company that needed to migrate their global library and clinical studies from an external Oracle Clinical instance to a BioPharm Systems hosted environment," said Michelle Engler, principal consultant, BioPharm Systems. "During the development of the solution, several other companies showed interest in its broad capabilities, so we decided to release it to the greater clinical trials community."
Pharmaceutical, biotechnology, and medical device companies, in addition to clinical research organizations and academic institutions who license the solution can choose to either employ it on their own or have BioPharm Systems service their specific needs. Although it has zero footprint in Oracle Clinical, the application's security is maintained via Oracle Clinical and its standard credential controls.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
